vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
Nutex Health, Inc. is the larger business by last-quarter revenue ($151.7M vs $123.8M, roughly 1.2× NATURES SUNSHINE PRODUCTS INC). Nutex Health, Inc. runs the higher net margin — 7.8% vs 3.3%, a 4.5% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $7.6M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 5.6%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
NATR vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $151.7M |
| Net Profit | $4.1M | $11.8M |
| Gross Margin | 72.5% | 30.4% |
| Operating Margin | 4.3% | 20.4% |
| Net Margin | 3.3% | 7.8% |
| Revenue YoY | 4.7% | -41.1% |
| Net Profit YoY | 1379.4% | -80.8% |
| EPS (diluted) | $0.23 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $151.7M | ||
| Q3 25 | $128.3M | $267.8M | ||
| Q2 25 | $114.8M | $244.0M | ||
| Q1 25 | $113.2M | $211.8M | ||
| Q4 24 | $118.2M | $257.6M | ||
| Q3 24 | $114.6M | $78.8M | ||
| Q2 24 | $110.6M | $76.1M | ||
| Q1 24 | $111.0M | $67.5M |
| Q4 25 | $4.1M | $11.8M | ||
| Q3 25 | $5.3M | $55.4M | ||
| Q2 25 | $5.3M | $-17.7M | ||
| Q1 25 | $4.7M | $21.2M | ||
| Q4 24 | $-321.0K | $61.6M | ||
| Q3 24 | $4.3M | $-8.8M | ||
| Q2 24 | $1.3M | $-364.0K | ||
| Q1 24 | $2.3M | $-364.0K |
| Q4 25 | 72.5% | 30.4% | ||
| Q3 25 | 73.3% | 57.8% | ||
| Q2 25 | 71.7% | 51.2% | ||
| Q1 25 | 72.1% | 55.9% | ||
| Q4 24 | 72.0% | 55.0% | ||
| Q3 24 | 71.3% | 27.8% | ||
| Q2 24 | 71.4% | 29.7% | ||
| Q1 24 | 71.2% | 15.1% |
| Q4 25 | 4.3% | 20.4% | ||
| Q3 25 | 7.0% | 48.7% | ||
| Q2 25 | 3.7% | 13.8% | ||
| Q1 25 | 5.4% | 38.1% | ||
| Q4 24 | 3.8% | 44.4% | ||
| Q3 24 | 4.6% | 12.3% | ||
| Q2 24 | 5.1% | 7.0% | ||
| Q1 24 | 4.2% | 2.1% |
| Q4 25 | 3.3% | 7.8% | ||
| Q3 25 | 4.2% | 20.7% | ||
| Q2 25 | 4.6% | -7.3% | ||
| Q1 25 | 4.2% | 10.0% | ||
| Q4 24 | -0.3% | 23.9% | ||
| Q3 24 | 3.8% | -11.2% | ||
| Q2 24 | 1.2% | -0.5% | ||
| Q1 24 | 2.1% | -0.5% |
| Q4 25 | $0.23 | $2.34 | ||
| Q3 25 | $0.30 | $7.76 | ||
| Q2 25 | $0.28 | $-2.95 | ||
| Q1 25 | $0.25 | $3.33 | ||
| Q4 24 | $-0.02 | $11.56 | ||
| Q3 24 | $0.23 | $-1.72 | ||
| Q2 24 | $0.07 | $-0.07 | ||
| Q1 24 | $0.12 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | $329.4M |
| Total Assets | $261.1M | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.9M | $185.6M | ||
| Q3 25 | $95.6M | $166.0M | ||
| Q2 25 | $81.3M | $96.7M | ||
| Q1 25 | $86.5M | $84.7M | ||
| Q4 24 | $84.7M | $40.6M | ||
| Q3 24 | $78.7M | $46.9M | ||
| Q2 24 | $68.7M | $40.8M | ||
| Q1 24 | $77.8M | $30.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | $161.6M | $329.4M | ||
| Q3 25 | $166.7M | $317.2M | ||
| Q2 25 | $163.7M | $235.3M | ||
| Q1 25 | $167.1M | $176.9M | ||
| Q4 24 | $161.0M | $132.4M | ||
| Q3 24 | $162.6M | $60.4M | ||
| Q2 24 | $156.4M | $62.7M | ||
| Q1 24 | $159.7M | $63.0M |
| Q4 25 | $261.1M | $918.5M | ||
| Q3 25 | $264.8M | $964.5M | ||
| Q2 25 | $254.9M | $841.0M | ||
| Q1 25 | $252.7M | $761.9M | ||
| Q4 24 | $240.9M | $655.3M | ||
| Q3 24 | $245.3M | $438.5M | ||
| Q2 24 | $235.8M | $422.4M | ||
| Q1 24 | $247.3M | $404.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $70.4M |
| Free Cash FlowOCF − Capex | $7.6M | $69.0M |
| FCF MarginFCF / Revenue | 6.1% | 45.5% |
| Capex IntensityCapex / Revenue | 1.9% | 0.9% |
| Cash ConversionOCF / Net Profit | 2.41× | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $70.4M | ||
| Q3 25 | $18.5M | $99.5M | ||
| Q2 25 | $4.3M | $27.3M | ||
| Q1 25 | $2.6M | $51.0M | ||
| Q4 24 | $12.2M | $54.0K | ||
| Q3 24 | $9.6M | $6.8M | ||
| Q2 24 | $1.3M | $13.3M | ||
| Q1 24 | $2.2M | $3.1M |
| Q4 25 | $7.6M | $69.0M | ||
| Q3 25 | $16.8M | $99.2M | ||
| Q2 25 | $3.0M | $26.5M | ||
| Q1 25 | $1.5M | $50.9M | ||
| Q4 24 | $10.0M | $-341.0K | ||
| Q3 24 | $7.9M | $6.2M | ||
| Q2 24 | $-2.0M | $12.7M | ||
| Q1 24 | $-1.5M | $2.3M |
| Q4 25 | 6.1% | 45.5% | ||
| Q3 25 | 13.1% | 37.0% | ||
| Q2 25 | 2.6% | 10.9% | ||
| Q1 25 | 1.3% | 24.0% | ||
| Q4 24 | 8.5% | -0.1% | ||
| Q3 24 | 6.9% | 7.8% | ||
| Q2 24 | -1.9% | 16.7% | ||
| Q1 24 | -1.4% | 3.4% |
| Q4 25 | 1.9% | 0.9% | ||
| Q3 25 | 1.3% | 0.1% | ||
| Q2 25 | 1.2% | 0.3% | ||
| Q1 25 | 1.0% | 0.0% | ||
| Q4 24 | 1.9% | 0.2% | ||
| Q3 24 | 1.5% | 0.8% | ||
| Q2 24 | 3.0% | 0.7% | ||
| Q1 24 | 3.3% | 1.1% |
| Q4 25 | 2.41× | 5.95× | ||
| Q3 25 | 3.46× | 1.80× | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | 0.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
